Please login to the form below

Not currently logged in
Email:
Password:

Vascepa

This page shows the latest Vascepa news and features for those working in and with pharma, biotech and healthcare.

Amarin sues FDA over off-label policy

Amarin sues FDA over off-label policy

the risk of heart disease, even though Vascepa itself has not yet been shown to achieve that objective in trials. ... In the meantime Vascepa is bringing in modest sales, with first-quarter turnover of around $15m, albeit up from $11m a year ago.

Latest news

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the ... Sales of Vascepa were around $26m in 2013, its first year on

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    Amarin slides as FDA panel votes against fish oil therapy. Advisory committee wants more data on Vascepa. ... population. By a 9-2 margin, the panel said it would not support approval of the omega-3 fatty acid based Vascepa (icosapent ethyl) as a

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics